Supplemental Table 4: Univariate analyses of baseline characteristics and ultrasonographic findings according to the number of large INVs

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Number of large INVs | LINVs Q1 | LINVs Q2 | LINVs Q3 | LINVs Q4 | *P* |
|  | Q1≤2 | 3≤Q2≤5 | 6≤Q3≤12 | 13≤Q4 |  |
|  | N=37 | N=25 | N=25 | N=28 |  |
| Age\* | 73.9±7.8 | 74.4±5.9 | 69.7±8.3 | 73.4±5.9 | 0.079 |
| Sex, male, n (%) | 31 (83.8%) | 18 (72.0%) | 23 (92.0%) | 24 (85.7%) | 0.28 |
| Symptomatic, n (%) | 21 (56.8%) | 11 (44. 0%) | 12 (48.0%) | 9 (32.1%) | 0.27 |
| Hypertension, n (%) | 30 (81.1%) | 21 (84.0%) | 19 (76.0%) | 16 (57.1%) | 0.088 |
| Diabetes mellitus, n (%) | 12 (32.4%) | 15 (60.0%) | 13 (52.0%) | 12 (42.9%) | 0.16 |
| Dyslipidemia, n (%) | 29 (78.4%) | 15 (60.0%) | 17 (68.0%) | 14 (50.0%) | 0.11 |
| Smoking, n (%) | 26 (70.3%) | 12 (48.0%) | 16 (64.0%) | 23 (82.1%) | 0.064 |
| Drinking, n (%) | 25 (67.6%) | 16 (64.0%) | 17 (68.0%) | 22 (78.6%) | 0.67 |
| Ischemic heart disease, n (%) | 10 (27.0%) | 4 (16.0%) | 8 (32.0%) | 6 (21.4%) | 0.57 |
| Peripheral arterial disease, n (%) | 3 (8.1%) | 1 (4.0%) | 1 (4.0%) | 3 (10.7%) | 0.71 |
| Statins, n (%) | 26 (70.3%) | 17 (68.0%) | 17 (68.0%) | 13 (46.4%) | 0.2 |
| Angiotensin receptor blockers, n (%) | 16 (43.2%) | 11 (44. 0%) | 13 (52.0%) | 8 (28.6%) | 0.37 |
| Antiplatelet drugs, n (%) | 33 (89.2%) | 21 (84.0%) | 23 (92.0%) | 21 (75.0%) | 0.29 |
| Degree of stenosis\* | 71.9±14.6 | 75.7±15.8 | 71.0±16.7 | 78.7±18.9 | 0.28 |

\*: Analysis of variance